PSMA PET Gallium Scan Approved by FDA
E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology, interviews Robert E. Reiter, MD, Bing Professor of Urology and Molecular Biology, Director of the Prostate Cancer Program, and Director of Urologic Research at the David Geffen School of Medicine at UCLA, on yesterday’s FDA approval of PSMA PET gallium scans for use in prostate cancer patients at the University of California, Los Angeles, and the University of California, San Francisco. Dr. Reiter, one of the investigators on the study that led to this, discusses how the approval, which was a joint effort between teams at UCLA and UCSF, is the first approval of a PSMA targeting agent in the United States, and will give new, potentially more effective options for urologists to stage prostate cancer for both newly-diagnosed and recurrent disease, leading to earlier detection of both metastatic disease and sites of recurrence, as well as improved overall management of the disease. They also discuss costs and potential insurance coverage at the currently-approved UCLA/UCSF sites and beyond, next steps for broader approval, and the implications of using PSMA PET in a theranostics approach to diagnosis and treatment of mCRPC and oligometastatic prostate cancer, as well as other disease states.
Видео PSMA PET Gallium Scan Approved by FDA канала Grand Rounds in Urology
Видео PSMA PET Gallium Scan Approved by FDA канала Grand Rounds in Urology
Показать
Комментарии отсутствуют
Информация о видео
2 декабря 2020 г. 21:35:24
00:08:03
Другие видео канала
![MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know](https://i.ytimg.com/vi/hJc8C0PAjdU/default.jpg)
![How to Differentiate the Causes of Lower Urinary Tract Symptoms](https://i.ytimg.com/vi/5WXIZ-PKhVA/default.jpg)
![Diagnosis & Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guidelines](https://i.ytimg.com/vi/CGhiubX4Jc8/default.jpg)
![Erectile Dysfunction: Perspective and Nuance from the 2018 AUA Guidelines](https://i.ytimg.com/vi/yRaSSxef9pk/default.jpg)
![Biochemical Recurrence After Local Therapy: Assessment and Management](https://i.ytimg.com/vi/8zxQ7kb22Yo/default.jpg)
![Improving Specificity of PSA Screening w/ Serum & Urine Markers: Who Doesn’t Need a Prostate Biopsy?](https://i.ytimg.com/vi/bgfuob3RSgE/default.jpg)
![Updates in LUTS: Treating Overactive Bladder and Nocturia](https://i.ytimg.com/vi/XfQFaUnkWF8/default.jpg)
![Treating BPH: Comparing HoLEP, Rezūm, UroLift, and Aquablation](https://i.ytimg.com/vi/sJz2DA6YvYU/default.jpg)
![PSMA PET Imaging in Advanced Prostate Cancer](https://i.ytimg.com/vi/6zB5xNn9MYM/default.jpg)
![Adjuvant or Salvage RT Post Radical Prostatectomy](https://i.ytimg.com/vi/JtzK1zgNdK0/default.jpg)
![Diet and Prostate Cancer—Now What?](https://i.ytimg.com/vi/_W3bA_gzX3Q/default.jpg)
![Surgical Treatment of Benign Prostatic Hyper-plasia: A Review of the 2018 AUA Guidelines](https://i.ytimg.com/vi/MSq25b5xppo/default.jpg)
![Gallium - a terminator metal](https://i.ytimg.com/vi/iPlhdzMKp6A/default.jpg)
![C11 Choline PET Scan by Dr Eugene Kwon](https://i.ytimg.com/vi/co4FIkDHsJc/default.jpg)
![Urologic Debate Part 2: MRI vs. Molecular Markers: Which One Should I Use? Markers Perspective](https://i.ytimg.com/vi/kcY6v8A0l4E/default.jpg)
![New Concepts in ADT](https://i.ytimg.com/vi/8Mo3EfPMed8/default.jpg)
![When to Biopsy: The Role for PSA and Novel Biomarkers](https://i.ytimg.com/vi/ivUVTuJwK-w/default.jpg)
![Current Diagnosis and Management of Female Stress Incontinence](https://i.ytimg.com/vi/IcgBKIPUqqc/default.jpg)
![Patient Selection for Focal Therapy: What is an Optimal Biopsy Strategy?](https://i.ytimg.com/vi/wr4p5hrC0mc/default.jpg)
![Telephone Techniques to Generate New Patients](https://i.ytimg.com/vi/dbkCLfPzOeI/default.jpg)